表紙
市場調查報告書

Biobetter和Biosimilar平台的技術進步

Technological Advances in Biobetter and Biosimilar Platforms

出版商 Frost & Sullivan 商品編碼 913135
出版日期 內容資訊 英文 67 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Biobetter和Biosimilar平台的技術進步 Technological Advances in Biobetter and Biosimilar Platforms
出版日期: 2019年09月20日內容資訊: 英文 67 Pages
簡介

在治療慢性疾病方面,更有效藥物是至關重要的需求。Biosimilar及Biobetter可降低治療各種慢性疾病的成本。

本報告研究Biobetter、Biosimilar平台的技術進步,彙整技術概要、市場潛力、策略建議等情報。

第1章 摘要整理

第2章 技術概要和趨勢

  • 兩種不同方法
  • 事實和機會
  • 缺點和挑戰

第3章 技術狀態概要和評估

  • 生物醫藥產業:營運趨勢
  • 商業發展
  • 商業生態系統
  • 技術趨勢
  • 製程優化、其他

第4章 技術雷達和智能解決方案

  • Biobetter:生化的改善
  • Biobetter:生物製造的改善
  • Biobetter:特性強化
  • 影響生物醫藥市場的Biosimilar PIPELINE
  • 按開發階段的PIPELINE產品
  • 按國家的PIPELINE產品
  • 按參考類型的PIPELINE產品

第5章 市場潛力和技術導入

第6章 商業環境和智慧財產權分析

第7章 技術ROADMAP

  • 典型價值鏈互動模式
  • 生物製造技術ROADMAP
  • 產業交叉模式
  • Crossmapping Biosimilar創新

第8章 最終見解和策略建議

  • 整體環境影響因素
  • 最佳產業合作夥伴:SWOT分析
  • 透過新商業模式讓Biosimilar和Biobetter獲利
  • 合作夥伴業務和技術能力
  • 未來成長的策略趨勢

第9章 產業聯絡資訊

目錄
Product Code: D8D5

Therapeutic Outcomes Optimization

Therapeutically more effective drugs for the treatment of chronic diseases represents a crucial need. Biosimilars and biobetters offer the possibility to lower the cost of treating a variety of chronic diseases. In particular, biosimilars are the less expensive option; however, biobetters have demonstrated to be more effective, even over longer periods of time as compared to biosimilars.

As the major factor propelling the market, both government and private sectors are progressively encouraging the usage of biosimilars and biobetters over conventional small molecules products. In particular, Asian countries count with skilled labor availability, lower manufacturing costs, and less strict regulatory instruments, so that the Asian market for biosimilars and biobetters is expected to experiment a significant growth in the coming five years.

The estimated expiration dates for patent, orphan and original approvals. Among them, patents constitute the main factor determining the moment in which biosimilars can enter the market.

The principal trends that are expected to favor the market over the next five years are leading manufacturers progressively focused on strategic collaborations, and a large number of market participants gradually outsourcing the production of biosimilar and biobetter products.

Manufacturers claim for flexible, modular solutions to gain versatility, and thereby become more efficient in terms of yields and costs. Principal trends involve multiple production volumes production on different scales to easily meet the demand by manufacturing multiple products in the same facility, and hence obtain higher profits.

Table of Contents

1.0 Executive Summary

  • 1.1 Research Focus - Biosimilars and Biobetters
  • 1.2 Research Scope - Foreseeing Challenges and Solutions
  • 1.3 Analysis Framework - Frost & Sullivan's Core Value
  • 1.4 Research Methodology

2.0 Technology Landscape and Trends

  • 2.1 Biosimilars and Biobetters - Two Different Approaches
  • 2.2 Biosimilars and Biobetters - Facts and Opportunities
  • 2.3 Biosimilars and Biobetters - Drawbacks and Challenges

3.0 Technology Status Review and Assessment

  • 3.1 The Biopharmaceutical Industry - Operational Trends
  • 3.2 The Biopharmaceutical Industry - Business Evolution
  • 3.3 The Biopharmaceutical Industry - Business Ecosystem
  • 3.4 The Biopharmaceutical Industry - Technology Focus
  • 3.5 The Biopharmaceutical Industry - Process Optimization
  • 3.6 The Biopharmaceutical Industry - Upstream Process
  • 3.7 The Biopharmaceutical Industry - Downstream Process
  • 3.8 Process Technology Disruptiveness Opportunities
  • 3.9 Bioprocessing Units and Facility Types - Fed Batch
  • 3.10 Large-scale Stainless Steel Fed Batch
  • 3.11 Bioprocessing Units and Facility Types - Single Use Bioreactors
  • 3.12 Single Use Bioreactors
  • 3.13 Bioprocessing Units and Facility Types - Small-scale Bioreactors
  • 3.14 Small Scale Bioreactors

4.0 Technology Radar and Intelligent Solutions

  • 4.1 Biobetters - Biochemical Improvements
  • 4.2 Biobetters - Biomanufacturing Improvements
  • 4.3 Biobetters - Enhanced Characteristics
  • 4.4 Biosimilars Pipeline Impacting the Biopharmaceutical Market
  • 4.5 Pipeline Products by Development Status
  • 4.6 Pipeline Products by Country
  • 4.7 Marketed Products by Reference Type

5.0 Market Potential and Technology Adoption

  • 5.1 Biosimilars and Biobetters Market Potential
  • 5.2 Biosimilars and Biobetters Market Forecast by Product Type
  • 5.3 Biosimilars and Biobetters Market Growth by Product Type
  • 5.4 Biosimilars and Biobetters Market Forecast by Region
  • 5.5 Biosimilars and Biobetters Market Growth by Region
  • 5.6 Market Adoption Trends for Biosimilars and Biobetters

6.0 Business Landscape and Intellectual Property Analysis

  • 6.1 Actionable Impact on Customers
  • 6.2 Repercussions in Business and Processes
  • 6.3 Patenting Trends and Major Focus
  • 6.4 Technology Transfer Assessment

7.0 Technology Roadmapping

  • 7.1 Typical Value Chain Interactive Model
  • 7.2 Biomanufacturing Technology Roadmap
  • 7.3 Industry Intersection Model
  • 7.4 Crossmapping Continuous Biosimilars Innovations

8.0 Final Insights and Strategic Recommendations

  • 8.1 Overall Environmental Impact Factors
  • 8.2 Best-fit Industry Partnerships - SWOT Analysis
  • 8.3 Novel Business Models to Monetize Biosimilars and Biobetters
  • 8.4 Partners Business and Technology Capabilities
  • 8.5 Strategic Imperatives for Future Growth

9.0 Key Industry Contacts

  • 9.1 Key Industry Influencers
  • 9.2 Key Industry Experts
  • 9.3 Key Industry Authorities
  • 9.4 Key Industry Advisors
  • 9.5 Key Industry Mentors
  • Legal Disclaimer
Back to Top